Nuvectis Pharma (NASDAQ:NVCT) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Nuvectis Pharma (NASDAQ:NVCT) issued its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.04, FiscalAI reports.

Nuvectis Pharma Price Performance

Shares of NVCT traded up $0.03 on Tuesday, reaching $8.92. The company’s stock had a trading volume of 49,342 shares, compared to its average volume of 60,196. The stock has a market capitalization of $246.68 million, a P/E ratio of -6.77 and a beta of -0.11. The stock’s 50 day simple moving average is $8.48 and its two-hundred day simple moving average is $7.76. Nuvectis Pharma has a 12-month low of $5.55 and a 12-month high of $11.15.

Hedge Funds Weigh In On Nuvectis Pharma

A number of institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. lifted its holdings in Nuvectis Pharma by 3,398.9% during the second quarter. JPMorgan Chase & Co. now owns 6,263 shares of the company’s stock valued at $47,000 after purchasing an additional 6,084 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Nuvectis Pharma during the second quarter valued at approximately $53,000. Bank of America Corp DE lifted its holdings in Nuvectis Pharma by 417.2% during the second quarter. Bank of America Corp DE now owns 8,565 shares of the company’s stock valued at $64,000 after purchasing an additional 6,909 shares in the last quarter. Deutsche Bank AG lifted its holdings in Nuvectis Pharma by 3,671.4% during the fourth quarter. Deutsche Bank AG now owns 12,672 shares of the company’s stock valued at $96,000 after purchasing an additional 12,336 shares in the last quarter. Finally, New York State Common Retirement Fund purchased a new position in Nuvectis Pharma during the second quarter valued at approximately $97,000. Hedge funds and other institutional investors own 96.77% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Nuvectis Pharma in a research note on Thursday, January 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $10.00.

About Nuvectis Pharma

Nuvectis Pharma is a clinical-stage biotechnology company focused on the development of novel peptide-based therapeutics using its proprietary Cellporting delivery platform. The company’s core technology is designed to facilitate the transport of therapeutic proteins and peptides across cellular membranes and into target intracellular compartments, including the nucleus. By overcoming a key barrier in biologics delivery, Nuvectis aims to expand the range of treatable diseases with macromolecular drugs that have traditionally been limited by poor cellular uptake.

The Nuvectis pipeline encompasses multiple preclinical and early-stage clinical programs targeting rare genetic and metabolic disorders.